LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
Ticker SymbolLNSR
Company nameLENSAR Inc
IPO dateSep 21, 2020
CEOMr. Nicholas T. (Nick) Curtis
Number of employees140
Security typeOrdinary Share
Fiscal year-endSep 21
Address2800 Discovery Drive
CityORLANDO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code32826
Phone18885367271
Websitehttps://www.lensar.com/
Ticker SymbolLNSR
IPO dateSep 21, 2020
CEOMr. Nicholas T. (Nick) Curtis
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data